Status:

TERMINATED

A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle

Lead Sponsor:

Fred Hutchinson Cancer Center

Collaborating Sponsors:

LUNGevity Foundation

Conditions:

Lung Carcinoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This clinical trial develops a tailored screening and smoking cessation program for the lesbian, gay, bisexual, transgender (trans) and queer (LGBTQ) community of Seattle, Washington. A lung cancer sc...

Detailed Description

OUTLINE: AIM 1: Stakeholders (community organization leaders, medical providers of LGBTQ patients, and LGBTQ community members and tobacco users) participate in an interview over 45 minutes to 1 hour...

Eligibility Criteria

Inclusion

  • AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Age minimum of 18
  • AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Affiliation with Cancer Consortium, Seattle's LGBTQ Center, or other organization serving LGBTQ persons
  • AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Identifies as providing primary care or specialty care to largely LGBTQ population (doctor of medicine \[MD\], registered nurse \[RN\], physician assistants \[PA\], advanced registered nurse practitioner \[ARNP\])
  • AIM 1, COMMUNITY ORGANIZATION LEADERS: Age minimum of 18
  • AIM 1, COMMUNITY ORGANIZATION LEADERS: Broadly defined as "community leader" (i.e. leadership in Seattle-area volunteer, philanthropic, community service groups) in discussions with with community-based participatory research (CBPR) partners
  • AIM 2: Current cigarette smoker (defined as actively smoking within the last 6 months, this is consistent with (c/w) standard and Seattle Cancer Care Alliance (SCCA) definition of "current smoker") or former cigarette smoker
  • AIM 2: Aged 50-80 years
  • AIM 2: At least 20 pack-year smoking history
  • AIM 3: Identify as a member of the LGBTQ community
  • AIM 3: Eligible for no-cost sharing LCS based on United States Preventive Services Task Force (USPSTF) criteria
  • As of Jan 2022: aged 50-80 years, at least 20 pack-year smoking history, and currently smoke tobacco cigarettes \[as this intervention is based around current cigarette smokers (as defined above)\], former cigarette smokers not included in this Aim

Exclusion

  • AIM 1: Non-English speaking participants
  • AIM 2: Those found to be ineligible for LCS on coordinator review; or who are non-English speaking or have cognitive dysfunction that would prevent participation in SDM
  • AIM 3: Those found to be ineligible for LCS on coordinator review; or who are non-English speaking or have cognitive dysfunction that would prevent participation in SDM

Key Trial Info

Start Date :

June 6 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 28 2024

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT05304390

Start Date

June 6 2022

End Date

October 28 2024

Last Update

December 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States, 98109